ÌÇÐÄ´«Ã½

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
ÌÇÐÄ´«Ã½

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.

ÌÇÐÄ´«Ã½

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. Journal of clinical oncology : official journal of the American Society of Clinical Oncology Roloff, G. W., Aldoss, I., Kopmar, N. E., Lin, C., Dekker, S. E., Gupta, V. K., O'Connor, T. E., Jeyakumar, N., Muhsen, I. N., Valtis, Y., Ahmed, N., Zhang, A., Miller, K., Dykes, K. C., Ahmed, M., Chen, E. C., Mercadal, S., Schwartz, M., Tracy, S. I., Dholaria, B., Mukherjee, A., Battiwalla, M., Logan, A. C., Ladha, A., Guzowski, C., Hoeg, R. T., Hilal, T., Moore, J., Connor, M. P., Hill, L. C., Tsai, S. B., Sasine, J. P., Solh, M. M., Kota, V. K., Koura, D., Veeraputhiran, M., Leonard, J. T., Frey, N. V., Park, J. H., Luskin, M. R., Bachanova, V., Galal, A., Pullarkat, V., Stock, W., Cassaday, R. D., Shah, B. D., Faramand, R., Muffly, L. 2024: JCO2400321

Abstract

On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October 2021 for adults with relapsed/refractory (R/R) B-cell ALL (B-ALL). We report outcomes of patients treated with brexu-cel as a standard therapy.We developed a collaboration across 31 US centers to study adults with B-ALL who received brexu-cel outside the context of a clinical trial. Data were collected retrospectively from October 2021 to October 2023. Toxicities were graded per American Society for Transplantation and Cellular Therapy guidelines for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).At the time of data lock, 204 patients had undergone apheresis and 189 were infused. Median follow-up time was 11.4 months. Forty-two percent of patients received brexu-cel in morphologic remission and would have been ineligible for participation in ZUMA-3. After brexu-cel, 151 achieved complete remission (CR), of which 79% were measurable residual disease (MRD) negative remissions. Median progression-free survival (PFS) was 9.5 months and median overall survival was not reached. Grade 3-4 CRS or ICANS occurred in 11% and 31%, respectively. In multivariable analysis, patients receiving consolidative hematopoietic cell transplantation (HCT; hazard ratio, 0.34 [95% CI, 0.14 to 0.85]) after brexu-cel had superior PFS compared with those who did not receive any consolidation or maintenance therapy.Similar to ZUMA-3, high rates of MRD-negative CR were observed after brexu-cel treatment for R/R B-ALL. The use of HCT as consolidation after brexu-cel resulted in improved PFS.

View details for

View details for